Article Versions Notes

Chun JW, Lee B, Park WS, Han N, Hong EK, Park EY, Han SS, Park S-J, Kim TH, Lee WJ, et al. RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. Journal of Clinical Medicine. 2021; 10(20):4652. https://doi.org/10.3390/jcm10204652

Chun, Jung Won, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, and et al. 2021. "RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin" Journal of Clinical Medicine 10, no. 20: 4652. https://doi.org/10.3390/jcm10204652

Chun, J. W., Lee, B., Park, W. S., Han, N., Hong, E. K., Park, E. Y., Han, S. S., Park, S.-J., Kim, T. H., Lee, W. J., & Woo, S. M. (2021). RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin. Journal of Clinical Medicine, 10(20), 4652. https://doi.org/10.3390/jcm10204652